{"@id":"https://bioecon.ru/technology/mucosal-vaccines-from-a-microbiota-platform/","@type":"Technology","cluster":"regenerative-personalized","formats":{"html":"https://en.bioecon.ru/technology/mucosal-vaccines-from-a-microbiota-platform/","json":"https://en.bioecon.ru/api/v1/technology/mucosal-vaccines-from-a-microbiota-platform/index.json"},"id":"mucosal-vaccines-from-a-microbiota-platform","industries":["pharma","biomanufacturing"],"lang":"en","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/lonza-group/","https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/ridgeway-biologicals/","https://bioecon.ru/companies/rubinum/","https://bioecon.ru/companies/vaxxinova-norway/","https://bioecon.ru/companies/hipra/","https://bioecon.ru/companies/esco-aster/"]},"maturity":7,"name":"Mucosal Vaccines from a Microbiota Platform","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"Microbiota OMV engineering"},{"n":2,"title":"Antigen surface display fusion"},{"n":3,"title":"Intranasal/sublingual dry powder delivery"},{"n":4,"title":"Sterilizing mucosal sIgA immunity"}],"summary":"Next-generation needle-free mucosal vaccine technologies exploiting commensal human microbiota-derived outer membrane vesicles (OMVs) and bacterial surface organelles (pili) to present intact viral and bacterial antigens directly to nasopharyngeal and bronchial mucosa, inducing high-affinity secretory IgA (sIgA) barriers that neutralize pathogens at the portal of entry.","url":"/technology/mucosal-vaccines-from-a-microbiota-platform/","verified":"2026-11-22"}